Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.40 |
| ▸ | CTSL | P07711 | 11/20 | 0.40 |
| ▸ | CTSS | P25774 | 11/20 | 0.40 |
| ▸ | CTSB | P07858 | 5/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629817 | 1.00 | CTSK (0.40) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6742391 | 1.00 | CTSK (0.40) | CTSKCTSLCTSSCTSBCTSV | |
| Hydrochloric Acid SCHEMBL5982642 | 0.99 | CTSK (0.40) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5983128 | 0.99 | CTSK (0.40) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6809592 | 0.87 | CTSK (0.50) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4686499 | 0.87 | CTSK (0.49) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6697424 | 0.87 | CTSK (0.50) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5971807 | 0.87 | CTSK (0.49) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5096647 | 0.86 | CTSK (0.42) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6740600 | 0.85 | CTSK (0.51) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20040229863-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20030114437-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-06-19 | — | — | US | disclosed |
| EP-1278502-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1278502-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001089451-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114437-A1 | Protease inhibitors | CTSS, CTSE, CTSF | CTSK 6/4885CTSL 24/4885CTSS 1/4885 |
| US-20040229863-A1 | Protease inhibitors | CTSS, CTSE, CTSF | CTSK 6/4885CTSL 24/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.